Karen White—Purdue Pharma

Karen White’s relationship with Purdue Pharma became a test of whether a former sales representative could prove that the company fired her for resisting its OxyContin marketing. Her 2003 lawsuit drew the hopes of Relatives Against Purdue Pharma, whose members saw her account as a way to challenge the company’s conduct in court. The jury ultimately ruled for Purdue, leaving the central conflict—White’s claim that she was punished for refusing to promote the drug to questionable prescribers—unproven under the legal standard applied at trial.

White’s work and the dispute over her dismissal

White was a thirty-six-year-old sales representative based in Lakeland, Florida. Early in her career, she had been a champion of OxyContin’s painkilling properties, an outlook shaped in part by witnessing her mother’s painful, premature death from cancer. Her later dispute with Purdue therefore arose not from a simple rejection of pain treatment, but from her claim that the company’s sales practices crossed a legal line.

Purdue said it fired White in 2002 because of paperwork irregularities, poor communication skills, and declining sales. White’s legal filing offered a different account: she said the real reason was that she refused to sell to doctors who were illegally overprescribing OxyContin. At trial, her attorney argued that Purdue had urged her to call on two doctors widely known for overprescribing. Both later lost their medical licenses for poor prescribing practices; one had exchanged prescription drugs for sex. White’s claim was that she had been dismissed for refusing to take part in aggressive promotion to doctors whose prescribing she believed was unlawful.

A lawsuit carrying other families’ hopes

Relatives Against Purdue Pharma’s parents followed White’s wrongful-termination case as a possible route to accountability. They believed that if a jury accepted her account, it would establish that Purdue’s marketing practices had crossed a legal boundary. Barbara Van Rooyan later described the scale of those hopes: supporters imagined White might become a figure who could help vindicate their effort.

That hope gave the case significance beyond White’s employment dispute. The organization had turned to courts after memorials and appeals to federal regulators had not produced the response its members sought. A legal victory, even one centered on a former employee rather than an addicted patient’s injury claim, might strengthen public scrutiny of Purdue and draw attention to OxyContin’s risks. White’s case thus joined two different stakes: compensation and recognition for a dismissed employee, and the families’ larger attempt to make the company answer for its promotion of the drug.

The trial also unfolded against Purdue’s public resistance to claims linking OxyContin to addiction. In the winter of 2003, the company announced that it had won sixty-five civil suits brought by people who blamed their addictions on the drug, presenting the record as a 65–0 result. Its general counsel, Howard Udell, said Purdue would continue to defend such cases vigorously and had not settled any of them. The company’s legal costs were mounting to about three million dollars a month, while 285 suits remained pending. This wider litigation campaign formed the backdrop to the hopes placed on White’s case, but did not itself establish what had happened in her employment relationship.

The trial and its outcome

In 2005, Ed Bisch drove twelve hours from Philadelphia to sit beside Lee Nuss in a Tampa federal courtroom. White was asking the jury for $138,000 in lost wages and $690,000 for emotional pain. Since her dismissal, she had been depressed and anxious, and she had never previously been fired from a job. Her case was the first lawsuit against Purdue to proceed beyond summary judgment, making the trial a rare opportunity to test allegations about the company’s sales practices before a jury.

Purdue arrived with a substantial legal team. Bisch counted ten lawyers on the company’s side, backed by the Atlanta firm King and Spalding. White had one attorney, who estimated that Purdue spent $500,000 defending the case; a company spokesperson declined to confirm that figure. The contrast in resources was part of the supporters’ experience of the trial, but the jury’s decision turned on whether White had proved her claim, not on the imbalance they perceived.

The jury ruled in Purdue’s favor. The company’s lawyer characterized the dispute as a personal disagreement over promoting the drug in a manner that was entirely legal. White believed that calling on the doctors amounted to illegal conduct, but her attorney did not prove that Purdue’s sales strategies violated the law. A government report sharply critical of Purdue’s marketing, issued by the Government Accountability Office in 2003, was ruled inadmissible at the request of a Purdue lawyer. The jury therefore did not decide the case on the basis of that report.

What the verdict established—and what it did not

Lee Nuss called Bisch after the verdict and told him that the money involved was simply too great, expressing the supporters’ sense that their effort had failed to move the system. For the families who had hoped White would prove that Purdue’s marketing crossed a legal line, the result was a severe setback. It did not, however, resolve every broader allegation against the company; it established that White had not proved the illegality of the sales strategies at issue in her own case.

Legal scholar Richard Ausness explained the evidentiary distinction as a demand that a plaintiff show what could be known and proved, rather than what she believed. The book places that distinction beside a larger record of litigation and regulatory criticism, including the exclusion of the 2003 government study. During OxyContin’s first decade, the legal system could not prove that the drug’s makers had broken the law. White’s defeat therefore marks both the specific limit of her lawsuit and the broader difficulty of converting serious concerns about marketing into a successful civil judgment.